Cellyan Biotechnology Files 6-K for December 2025

TL;DR

Cellyan Biotech (fka Hong Kong Pharma) filed a 6-K for Dec 2025, confirming 20-F annual reports.

AI Summary

Cellyan Biotechnology Co., Ltd. (formerly Hong Kong Pharma Digital Technology Holdings Ltd) filed a Form 6-K on December 31, 2025, for the month of December 2025. The company, incorporated in E9 with a fiscal year end of March 31, is a wholesale distributor of proprietary drugs and druggists' sundries. The filing indicates they will file annual reports under Form 20-F.

Why It Matters

This filing provides routine disclosure for Cellyan Biotechnology, a foreign private issuer, updating the SEC on its status and reporting requirements.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer and does not contain significant new financial or operational information.

Key Players & Entities

• Cellyan Biotechnology Co., Ltd (company) — Registrant
• Hong Kong Pharma Digital Technology Holdings Ltd (company) — Former company name
• 20251231 (date) — Filing date
• December 2025 (date) — Reporting period
• 001-42468 (other) — SEC file number

FAQ

Key Financial Figures

• $100,000 — zed share capital of the Company from US$100,000 divided into 100,000,000 ordinary share
• $0.001 — 000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,00
• $1,000,000 — hares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary sha

Filing Documents

• ea0271326-6k_cellyan.htm (6-K) — 18KB
• ea027132601ex1-1_cellyan.htm (EX-1.1) — 1KB
• ea027132601ex1-2_cellyan.htm (EX-1.2) — 312KB
• ex1-1_001.jpg (GRAPHIC) — 357KB
• ex1-2_001.jpg (GRAPHIC) — 94KB
• 0001213900-25-126836.txt ( ) — 954KB

From the Filing

OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2025 Commission File Number 001-42468 Cellyan Biotechnology Co., Ltd (Registrant’s Name) Room B1, 5/F., Well Town Industrial Building, 13 Ko Fai Road, Yau Tong, Kowloon Hong Kong (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F INFORMATION CONTAINED IN THIS FORM 6-K REPORT As previously disclosed on the report on Form 6-K of Cellyan Biotechnology Co., Ltd (f.k.a. Hong Kong Pharma Digital Technology Holdings Limited), a Cayman Islands exempted company with limited liability (the “Company”) at the annual general meeting of shareholders of the Company held on December 12, 2025, it was approved and authorized, among others, that (i) an increase of the authorized share capital of the Company from US$100,000 divided into 100,000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001; (ii) an amendment of the authorized share capital of the Company from US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of $0.001 each, to US$1,000,000 divided into 1,000,000,000 ordinary shares of par value of US$0.001 each, comprising (i) 940,000,000 class A ordinary shares of par value of US$0.001 each and (ii) 60,000,000 class B ordinary shares of par value of US$0.001 each; (iii) the English name of the Company be changed from “Hong Kong Pharma Digital Technology Holdings Limited” to “Cellyan Biotechnology Co., Ltd”, and the Chinese name of “” be adopted as the dual foreign name of the Company to replace its existing Chinese name of “” with effect from the date on which the Registrar of Companies in the Cayman Islands issues a Certificate of Incorporation on Change of Name confirming that the new name has been registered, and each of the directors and the secretary and the registered office provider of the Company be and is hereby authorized severally to do all such acts and things and execute all such documents as he/she/it may consider necessary, desirable, appropriate or expedient to implement and/or give effect to the proposed change of company name and to attend to any necessary registration and/or filing for and on behalf of the Company; and (iv) the Fourth Amended and Restated Memorandum and Articles of Association of the Company be approved and adopted as the memorandum and articles of association of the Company in substitution for, and to the exclusion of, the existing third amended and restated memorandum and articles of association of the Company, and each of the directors and the secretary and the registered office provider of the Company be and is hereby authorized severally to do all such acts and things and execute all such documents as he/she/it may consider necessary, desirable, appropriate or expedient to implement the adoption of the Fourth Amended and Restated Memorandum and Articles of Association. Attached to this report on Form 6-K as Exhibit 1.1 is a copy of the Certificate of Incorporation on Change of Name and Exhibit 1.2 is a copy of the Fourth Amended and Restated Memorandum and Articles of Association of the Company. 1 EXHIBIT INDEX Exhibits Exhibit No. Description 1.1 Certificate of Incorporation on Change of Name 1.2 Fourth Amended and Restated Memorandum and Articles of Association 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellyan Biotechnology Co., Ltd. By: /s/ Chenyu Liang Name: Chenyu Liang Title: Director and Chief Executive Officer Date: December 30, 2025 3

View Full Filing

View this 6-K filing on SEC EDGAR